About 18,880 results

ALLMedicine™ Acute Lymphoblastic Leukemia Center

Research & Reviews  6,362 results

Treatment of children with acute lymphoblastic leukemia in Cambodia.
Pediatric Blood & Cancer; Küpfer L, Meng B et. al.

Jul 29th, 2021 - We report a retrospective analysis of 110 unselected pediatric patients with acute lymphoblastic leukemia (ALL) treated during 2015-2017 in a charity-funded public institution in Cambodia with a reduced intensity ALL-Moscow Berlin (MB)-91 protocol...

Therapeutic strategies, including allogeneic stem cell transplantation, to overcome rel...
Expert Review of Hematology; Baek DW, Lee JM et. al.

Jul 28th, 2021 - The long-term survival of relapsed/refractory (R/R) adult T-cell acute lymphoblastic leukemia (T-ALL) is quite poor, and early T-cell precursor (ETP) ALL has recently been described as a high-risk T-ALL subgroup. However, the optimal therapeutic a...

CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or re...
https://doi.org/10.1038/s41591-021-01436-0 10.1172/JCI85309 10.1016/S1470-2045(18)30864-7 10.1056/NEJMoa1707447 10.1056/NEJMoa1804980 10.1182/blood-2018-11-883710 10.1056/NEJMoa1709866 10.1056/NEJMoa1709919 10.1200/JCO.19.02104 10.1182/blood-2019-127508 10.1016/S0140-6736(14)61403-3 10.1056/NEJMoa1910607 10.1158/2159-8290.CD-18-0442 10.1128/MCB.00383-18 10.1038/s41375-019-0580-z 10.1038/s41591-018-0146-z 10.1158/2159-8290.CD-15-1020 10.1158/1078-0432.CCR-18-0432 10.4049/jimmunol.1402346 10.1038/mt.2016.82 10.1016/j.ymthe.2017.06.008 10.1158/2159-8290.CD-19-0945 10.1038/nm.4441 10.1172/JCI126397 10.1182/blood-2018-99-120206 10.1182/blood-2019-126218 10.1002/pbc.25410 10.1182/blood-2012-06-438002 10.1016/S0065-2776(05)88001-0 10.3109/10428194.2011.559668 10.1080/08820130500496878 10.1200/JCO.19.03279 10.1016/j.omto.2018.10.006 10.1126/science.aba1786 10.1002/ajh.24594 10.1182/blood.2020009432 10.1182/blood-2015-08-665547 10.1038/ncomms12320 10.1056/NEJMoa1708566 10.3324/haematol.2017.183459 10.1182/blood-2016-04-711903 10.1172/JCI83416 10.1093/neuonc/nox182 10.1038/s41467-020-16160-5 10.1182/blood.2019002779 10.1182/bloodadvances.2019000703 10.1038/s41591-020-1081-3 10.1182/blood-2020-140907 10.1200/JCO.2020.38.15_suppl.3035 10.1038/s41375-020-0792-2 10.1186/s13045-020-00856-8 10.1182/blood-2019-123424 10.1038/s41586-019-1805-z 10.1097/01.cji.0000161397.96582.59 10.1158/1078-0432.CCR-13-0330 10.4161/onci.23621 10.1053/j.gastro.2020.02.011 10.1182/blood-2019-131024 10.1038/mtna.2013.32 10.1158/2326-6066.CIR-15-0231 10.1007/s00262-018-2155-7 10.1182/blood-2014-01-552174 10.1182/bloodadvances.2020003092 10.1200/JCO.2013.54.8800 10.1182/blood-2014-05-552729 10.1016/j.bbmt.2018.12.758 10.1093/nar/gkm861 10.1371/journal.pone.0057838 10.1186/s12885-020-07077-9
Nature Medicine; Spiegel JY, Patel S et. al.

Jul 28th, 2021 - Despite impressive progress, more than 50% of patients treated with CD19-targeting chimeric antigen receptor T cells (CAR19) experience progressive disease. Ten of 16 patients with large B cell lymphoma (LBCL) with progressive disease after CAR19 ...

Blinatumomab vs Chemotherapy Among Children With Relapsed Acute Lymphoblastic Leukemia-...
JAMA Locatelli F, Zugmaier G et. al.

Jul 28th, 2021 - Blinatumomab vs Chemotherapy Among Children With Relapsed Acute Lymphoblastic Leukemia-Reply.|2021|Locatelli F,Zugmaier G,von Stackelberg A,|

Blinatumomab vs Chemotherapy Among Children With Relapsed Acute Lymphoblastic Leukemia.
JAMA Shibusawa M, Kidoguchi K et. al.

Jul 28th, 2021 - Blinatumomab vs Chemotherapy Among Children With Relapsed Acute Lymphoblastic Leukemia.|2021|Shibusawa M,Kidoguchi K,Tanimoto T,|

see more →

Guidelines  3 results

Pediatric Acute Lymphoblastic Leukemia, Version 2.2020, NCCN Clinical Practice Guidelin...
Journal of the National Comprehensive Cancer Network : JN... Brown P, Inaba H et. al.

Jan 8th, 2020 - Acute lymphoblastic leukemia (ALL) is the most common pediatric malignancy. Advancements in technology that enhance our understanding of the biology of the disease, risk-adapted therapy, and enhanced supportive care have contributed to improved su...

NCCN Guidelines Insights: Acute Lymphoblastic Leukemia, Version 1.2017.
Journal of the National Comprehensive Cancer Network : JN... Brown PA, Shah B et. al.

Sep 7th, 2017 - The prognosis for patients with newly diagnosed acute lymphoblastic leukemia (ALL) has improved with the use of more intensive chemotherapy regimens, tyrosine kinase inhibitors, targeted agents, and allogeneic hematopoietic cell transplantation. H...

Role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment...
Biology of Blood and Marrow Transplantation : Journal of ... Oliansky DM, Camitta B et. al.

Jan 3rd, 2012 - Clinical research published since the first evidence-based review on the role of hematopoietic stem cell transplantation (SCT) in the treatment of pediatric acute lymphoblastic leukemia (ALL) is presented and critically evaluated in this update. T...

see more →

Drugs  109 results see all →

Clinicaltrials.gov  386 results

A Study Of Two Inotuzumab Ozogamicin Doses in Relapsed/ Refractory Acute Lymphoblastic Leukemia Transplant Eligible Patients

May 7th, 2020 - This study will explore 2 different doses of inotuzumab ozogamicin including the dose that is approved and a lower dose. The main purpose of this study is to evaluate whether a dose of inotuzumab ozogamicin, lower than the approved dose, could be ...

Study Evaluating the Efficacy and Safety of JCAR015 in Adult B-cell Acute Lymphoblastic Leukemia (B-ALL)

May 4th, 2020 - This is a single-arm, multicenter Phase 2 study to determine the efficacy and safety of JCAR015 in adult patients with relapsed or refractory B-ALL. The study will have the following sequential phases: Part A (screening, leukapheresis, cell produc...

211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome

May 1st, 2020 - OUTLINE: This is a dose-escalation study of astatine At 211 anti-CD45 monoclonal antibody BC8-B10. PREPARATIVE REGIMEN: Patients receive astatine At 211 anti-CD45 monoclonal antibody BC8-B10 infusion on day -8, fludarabine intravenously (IV) over ...

Augmentation of the Graft vs. Leukemia Effect Via Checkpoint Blockade With Pembrolizumab

Apr 28th, 2020 - This is a single arm, open-label, Phase 1b study of pembrolizumab for patients with myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), and acute lymphoblastic leukemia (ALL) whose disease has relapsed after receiving allogeneic hematopo...

Cancer Care Delivery in Adolescent and Young Adult Patients With Acute Lymphoblastic Leukemia

Apr 27th, 2020 - PRIMARY OBJECTIVES: I. To evaluate the proportion of adolescent and young adult (AYA) acute lymphoblastic leukemia (ALL) patients with a documented treatment plan consistent with NCCN guidelines for AYAs with ALL. II. To evaluate the proportion of...

see more →

News  689 results

FDA Approves New Asparaginase Product for Leukemia

Jul 2nd, 2021 - The US Food and Drug Administration (FDA) has approved a new version of asparaginase for use in children and adults who have developed hypersensitivity to asparaginase derived from Escherichia coli. The new product is Jazz Pharmaceutical's Rylaze ...

Venetoclax Shows Activity Against T-ALL in Children

Jun 3rd, 2021 - Data from a small retrospective study suggest that venetoclax-based regimens may have activity against relapsed or refractory T-lineage acute lymphoblastic leukemia (T-ALL) in children and young adults. Among seven patients with T-ALL treated with...

Sex Differences in Pediatric B-ALL Outcomes Persist

May 21st, 2021 - Even in the age of intensive therapy and extensive risk stratification, there are small but significant differences in outcomes between boys and girls with B-lineage acute lymphoblastic leukemia (B-ALL). This finding comes from a review of 10 year...

Low-Calorie Diet Linked to Improved Chemo Response in Leukemia

Apr 7th, 2021 - Children and adolescents with leukemia who were placed on a restrictive diet and exercise regimen concurrent with starting chemotherapy showed responses to treatment that were better than those historically seen in such patients. This apparently i...

Allo-HSCT Plus MAb Can Boost Survival in Patients With r/r B-ALL

Mar 25th, 2021 - The use of allogeneic hematopoietic stem cell transplantation (allo-HSCT) can improve survival in minimal residual disease (MRD)-negative remission patients with relapsed/refractory (r/r) B-cell acute lymphoblastic leukemia (B-ALL) after the start...

see more →

Patient Education  3 results see all →